Highlights

  • HC Wainwright & Co. revised Agenus rating from Neutral to Buy on June 4, 2025
  • Analyst consensus price target is USD 6.46, up from current price of USD 5.00
  • Institutional ownership increased 10.99% in the past quarter to 10.6 million shares

On June 4, 2025, HC Wainwright & Co. upgraded its rating for Agenus (NasdaqCM: AGEN) from Neutral to Buy, reflecting a change in analyst sentiment. The firm’s updated outlook comes as the average one-year price target for the clinical-stage immuno-oncology company rises to USD 6.46 per share, suggesting a 29.20% upside from the June 2 closing price of USD 5.00.

Price targets among analysts vary, with the lowest estimate at USD 4.04 and the highest at USD 8.40. While the projections indicate moderate upside, they also reflect differing views on the company’s future performance amid ongoing clinical development efforts.

Agenus is projecting annual revenue of USD 138 million, a 38.53% increase from the prior year, despite still operating at a loss. Its forecasted non-GAAP earnings per share (EPS) stands at -USD 0.71, indicating that profitability remains out of reach in the near term.

Institutional sentiment has shifted slightly. There are 194 institutions reporting positions in AGEN, up by 2.11% over the last quarter. The total number of shares held by institutions increased 10.99% to 10.6 million shares. Additionally, the average portfolio weight across funds with AGEN exposure rose 13.92% to 0.02%.

While the analyst upgrade and improved fund sentiment point to increased interest, Agenus remains a clinical-stage company with ongoing financial losses and product development risks.